PARK2 (PDJ, PRKN, AR-JP, LPRS2, E3 Ubiquitin- Protein Ligase Parkin, Parkinson Juvenile Disease Protein 2, Parkinson Disease Protein 2)

Antibodies / Antibodies-Ubiquitin Ligases

-20°C

Supplied as a liquid in PBS, 0.02% sodium azide.

Peptide corresponding to 17aa from human PARK2 at N-terminal.

Parkinson’s disease (PD) is a neurodegenerative disease whose symptoms include tremors, rigidity, bradykinesia, and postural instability (1). Mutations in the PARK2 gene are known to cause Parkinson disease and autosomal recessive juvenile Parkinson disease (2). The PARK2 protein is a component of a multiprotein E3 ubiquitin ligase complex that mediates the targeting of substrate proteins for proteasomal degradation (3). Recent studies have suggested that PARK2 expression reduces the mitochondrial accumulation of the apoptosis protein Bax under basal conditions and directly ubiquitinates Bax, thereby promoting cell survival (4).

Applications:
Suitable for use in Immunofluorescence, ELISA, Western Blot and Immunohistochemistry. Other applications not tested.

Recommended Dilution:
Immunofluorescence: 20ug/ml
Western Blot: 1-2ug/ml
Immunohistochemistry (paraffin): 5ug/ml
Optimal dilutions to be determined by the researcher.

Positive Control:
Human Cerebellum Tissue Lysate

Storage and Stability:
May be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Aliquots are stable for 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.